✦ LIBER ✦

A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis

✍ Scribed by Genovese, Mark C. (author);Cohen, Stanley B. (author);Wofsy, David (author);Weinblatt, Michael E. (author);Firestein, Gary S. (author);Brahn, Ernest (author);Strand, Vibeke (author);Baker, Daniel G. (author);Tong, Sandra E. (author)

Book ID: 123607059
Publisher: Journal of Rheumatology Publishing Company
Year: 2011
Tongue: English
Weight: 320 KB
Volume: 38
Category: Article
ISSN: 0315-162X
DOI: 10.3899/jrheum.100602

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A 24-Week, Randomized, Double-Blind, Pla

A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis

✍ Genovese, Mark C. (author);Cohen, Stanley B. (author);Wofsy, David (author);Wein 📂 Article 📅 2011 🏛 Journal of Rheumatology Publishing Company 🌐 English ⚖ 320 KB

Evaluation of the efficacy and safety of

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

✍ Stanley B. Cohen; Tien-Tsai Cheng; Vishala Chindalore; Nemanja Damjanov; Ruben B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

Oral laquinimod in patients with relapsi

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

✍ Comi, G.; Abramsky, O.; Arbizu, T.; Boyko, A.; Gold, R.; Havrdova, E.; Komoly, S 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 307 KB

An oral Syk kinase inhibitor in the trea

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

✍ Mark C. Genovese; Arthur Kavanaugh; Michael E. Weinblatt; Charles Peterfy; Julie 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 2 views

Evaluation of the efficacy and safety of

Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: Results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

✍ Oliver Distler; Wolfgang Eich; Eva Dokoupilova; Zdenek Dvorak; Martin Fleck; Mar 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ W. Rigby; H.-P. Tony; K. Oelke; B. Combe; A. Laster; C. A. von Muhlen; E. Fishel 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views